🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses

EntrackrEntrackr · 3m ago
Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses
Medial

Redcliffe Labs posts Rs 419 Cr revenue in FY25; narrows EBITDA losses Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24 and managed to narrow its EBITDA losses, as per the company’s press release. Diagnostics platform Redcliffe Labs has posted a 20% increase in its operating revenue to Rs 419 crore in FY25 from Rs 350 crore in FY24, as per the company’s press release. The Gurugram-based firm also managed to reduce its EBITDA losses from -38% to -21% during the same period. Founded by Aditya Kandoi, Redcliffe operates a nationwide network of over 80 labs and claims to have the widest home sample collection footprint in the country. Diagnostic services contributed over 95% of the company’s revenue in FY25, with the rest coming from product sales and other operating income. The company said it diagnosed over 2.5 million cases last fiscal and continues to focus on expanding in underserved regions, with more than 70% of its testing volumes now coming from Tier II cities and beyond. On the profitability front, Redcliffe reported a gross margin of 70% in FY25 and is aiming to expand it to 74% in FY26. It has also set a revenue target of Rs 560 crore for the ongoing fiscal through organic growth and strategic acquisitions. “We are transforming lives and making diagnostics a first-line solution for millions who were previously underserved,” said Kandoi. The company plans to expand its presence to over 300 cities with 150 labs by FY28. According to startup data platform TheKredible, Redcliffe has raised $113 million to date, including a $42 million Series C round led by LeapFrog. It also acquired Bengaluru-based Celara Diagnostics in a $7 million deal. Redcliffe competes with players like PharmEasy-owned Thyrocare, Tata 1mg, and Healthians.

IVY Growth launches Rs 250 Cr Arigato Capital fund

EntrackrEntrackr · 1y ago
IVY Growth launches Rs 250 Cr Arigato Capital fund
Medial

Micro venture capital firm IVY Growth Associates has announced the launch of Arigato Capital, a SEBI-registered Category I AIF Venture Capital (VC) fund, with a target corpus of Rs 250 crore. This sector-agnostic fund is set to invest in startups across a variety of sectors, including agritech, cleantech, generative AI, fintech, consumer brands, and software-as-a-service (SaaS) companies, the fund said in a press release. Arigato Capital aims to begin raising capital in June 2024, with plans to close all commitments over the next 15 to 18 months. The Venture Capital (VC) fund targets a first close at Rs 100 crore and will focus on startups beyond the seed stage or in pre-series A stages, offering an average ticket size of $500,000. Founded by Prateek Toshniwal, Rachit Poddar, Mehul Shah, and Sharad Todi, IVY Growth Associates claims to have invested in over 100 growth-stage startups. The firm has deployed Rs 20 crore from its fund and utilized more than Rs 80 crore from syndicate funds within its network. IVY’s portfolio includes notable brands such as Rupeek, BluSmart, and Zappfresh. In addition to launching Arigato Capital, IVY Growth Associates will host the third edition of its startup summit, 21 BY 72, from June 15 to June 16 in Surat. The summit is expected to attract over 20,000 participants, including more than 200 startup founders, 200 venture capitalists, and over 500 investors.

Sterling Accuris’ revenue surpasses Rs 200 Cr in FY25, turns EBITDA positive

EntrackrEntrackr · 4d ago
Sterling Accuris’ revenue surpasses Rs 200 Cr in FY25, turns EBITDA positive
Medial

Sterling Accuris’ revenue surpasses Rs 200 Cr in FY25, turns EBITDA positive Sterling Accuris Diagnostics managed 22% YoY growth in its operating scale during the fiscal year ending March 2025. Significantly, the Ahmedabad-based firm also narrowed its losses and turned EBITDA positive during the last fiscal year. The company’s revenue from operations grew to Rs 198 crore in FY25 from Rs 162 crore in FY24, its consolidated financial statements sourced from the Registrar of Companies (RoC) show. Founded in 2014, Sterling Accuris Diagnostics offers over 2,000 tests through around 150 labs and collection centers across four states, with testing services as its sole source of revenue. The firm made additional Rs 4 crore from non-operating sources which drove its total income to Rs 202 crore in FY25 from Rs 169 crore in FY24. When it comes to spending, employee benefits were the largest expense at Rs 52 crore, increasing 18% from Rs 44 crore in FY24, followed by material costs at Rs 45 crore and doctor and pathologist fees at Rs 40 crore. Depreciation charges stood at Rs 19 crore, while finance cost was Rs 6 crore in the last fiscal year. Overall, Sterling Accuris Diagnostics’ total expense increased by 14% to Rs 221 crore in FY25 from Rs 194 crore in FY24. With revenue outpacing expense growth, the firm controlled its loss by 15% to Rs 23 crore in FY25 from Rs 27 crore in FY24. Importantly, it posted a positive EBITDA of Rs 5.5 crore in FY25 with EBITDA margin improving to 2.72% from -0.59%. Sterling Accuris Diagnostics’ ROCE stood at -7.07%. On a unit basis, Sterling Accuris spent Rs 1.12 to earn a rupee in FY25, an improvement from Rs 1.20 in FY24. As of March 2025, the company recorded current assets worth Rs 52 crore in FY25 including Rs 22 crore in cash and bank balances. According to TheKredible, Sterling Accuris has raised a total of $33 million of funding till date. Its lead investors are Morgan Stanley, holding a 35.64% stake, and Udhay Vi Realty, with a 17%.

Download the medial app to read full posts, comements and news.